Which ICD-10-CM codes should be assigned for a patient undergoing chemotherapy for primary hepatocellular carcinoma?

• A. Z51.11, C22.0
• B. Z51.11, C22.0, C80.2
• C. Z51.11, T86.49, C80.2, C22.0
• D. None of the above

Answer: (C)

The correct choice involves understanding the appropriate ICD-10-CM codes for a patient undergoing chemotherapy specifically for primary hepatocellular carcinoma.

The code Z51.11 is used to indicate outpatient chemotherapy visit. It reflects that the patient is receiving treatment aimed at cancer management, which is crucial for capturing the reason for the patient's hospital visits.

The code C22.0 is designated specifically for hepatocellular carcinoma, or liver cancer. This coding is essential because it directly ties the diagnosis to the therapeutic intervention documented by the Z51.11 code.

Additionally, C80.2 is relevant as it represents "Malignant neoplasm without specification of site" and may be utilized when documenting the spread or presence of cancer that does not fit neatly into a single diagnosis. It allows for a more comprehensive capture of the patient's oncology status and any potential metastasis that may be relevant.

Including T86.49, which indicates "Failure or loss of other organ transplanted," suggests that there may have been a history of liver transplant or similar issue, which would be pertinent in the context of hepatocellular carcinoma treatment and its complications, although it might not be specifically indicative of the chemotherapy process itself.

Thus, the combination of these codes captures the entire